Real-world data from Peru, which has used the jab, shows two doses only cut the risk of infection by 50.4 per cent. However, the data also showed the jab was still in the region of 94 per cent effective at cutting the risk of death. The study of 400,000 healthcare staff in Peru found that Sinopharm is just 50.4 per cent effective against infection. And countries including Cambodia and the UAE have already offered boosters using the UK and US vaccines to people who received Sinopharm's. The jab was originally found to be 78.1 per cent effective in clinical trials, according to the WHO.

Source: Daily Mail August 13, 2021 17:23 UTC